August 8, 2022

Medical Trend

Medical News and Medical Resources

New lipid-lowering drug PCSK9 inhibitor much better than Statins

New lipid-lowering drug PCSK9 inhibitor much better than Statins



 

New lipid-lowering drug PCSK9 inhibitor much better than Statins.

The new lipid-lowering drug PCSK9 inhibitor is more potent and safer than statins, once every six months.

 

 

New lipid-lowering drug PCSK9 inhibitor much better than Statins

 

 

For patients with hyperlipidemia and coronary heart disease, statins must not be unfamiliar, but if you tell you that there is a lipid-lowering drug that is more effective than statins, and it only needs to be used once every six months, is it heartbeat? How do you feel? Yes, there is such a lipid-lowering drug.

They can be collectively referred to as proprotein convertase subtilisin 9 (PCSK9) inhibitors. The latest long-acting drug inclisiran can last for up to 180 days after one injection. Still in clinical trials.

 

Among similar drugs, two short-acting PCSK9 inhibitor formulations have been marketed in China: Iloiuumab and Aliciyuumab, both of which can be injected once every two weeks or monthly.

Although these two drugs are not long-acting preparations, they also have considerable advantages compared with statins. Today we will take stock.

 

 

 

A new way of working

In 2003, researchers found a mutation in PCSK9 in the families of two French patients with familial hypercholesterolemia.

Gain-of-function or loss-of-function mutations in this gene can cause a significant increase or decrease in low-density lipoprotein (LDL) levels.

Therefore, inhibiting the PCSK9 mutant gene can reduce blood lipid levels and prevent atherosclerosis.

 

At present, statins are still the first choice for the treatment of hyperlipidemia in clinical practice.

However, it has also been found clinically that even if some patients take large doses of statins, their LDL levels still cannot reach the ideal level, and large doses of statins are given to patients The security issues brought about cannot be ignored either.

Later, researchers found that these mainstream lipid-lowering drugs, such as statins and fibrates, can increase PCSK9 levels. This may be the reason why some patients use statins to reduce LDL levels unsatisfactorily.

 

Through further research, PCSK9 inhibitors came into being, and quickly attracted everyone’s attention with a new mode of action and higher safety.

 

 

 

Stronger lipid-lowering effect

There is a meta-analysis comparing the effects of PCSK9 inhibitors and other lipid-lowering drugs. Compared with ezetimibe, PCSK9 inhibitors can further reduce LDL levels by 30.2%; compared with statins, the study found that patients using statins reduced LDL on average by 46.25%, while using PCSK9 inhibitors can reduce LDL levels on average by 52.66%;

In addition, PCSK9 inhibitors have obvious advantages compared with statins combined with ezetimibe, which can further reduce LDL by 39.2%. Not only that, the study also found that PCSK9 inhibitors significantly reduced non-high-density lipoprotein, total cholesterol, triglyceride, apolipoprotein and other blood lipid levels.

 

 

 

Better prevention of cardiovascular disease risk

Studies have shown that, compared with placebo, PCSK9 inhibitors can significantly reduce the risk of cardiovascular events in diabetic and non-diabetic patients.

This benefit has no significant difference between diabetic and non-diabetic patients, and can also significantly reduce the original The risk of cardiovascular events in patients with peripheral arterial disease.

In terms of the primary endpoint, PCSK9 inhibitors can significantly reduce the risk of cardiovascular death, myocardial infarction, stroke, and unstable angina requiring hospitalization.

 

 

 

Higher security

Different from the adverse reactions caused by statins, such as rhabdomyolysis, liver damage, and blood sugar effects, from the perspective of currently marketed PCSK9 inhibitors, it is well tolerated by patients when administered by subcutaneous injection.

The main adverse reactions are allergic reactions and injection site reactions caused by its immunogenicity.

Compared with placebo, there is no significant increase, including the occurrence of muscle-related reactions and elevated transaminases, which is safer.

 

 

 

More long-lasting

The two short-acting formulations that have been on the market, iloyuumab and alisiyuumab, only need to be injected once every two weeks or every month. Inclisiran, which is currently in clinical trials, can be injected once every six months, which greatly improves Patient compliance.

 

 

 


Sum up

Finally, because PCSK9 inhibitors have been on the market soon and have more advantages compared with traditional lipid-lowering drugs, their prices are currently higher, and patients can choose to use them according to their own economic conditions, especially if they are intolerant to statins.

Patients with abnormal liver function and muscle pain after taking statins may consider such drugs.

 

 

 

 

New lipid-lowering drug PCSK9 inhibitor much better than Statins

(source:internet, reference only)


Disclaimer of medicaltrend.org